MDxHealth (MDXH) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'
MDxHealth reports Q2 sales growth, mixed earnings and reaffirmed 2026 revenue guidance as tissue test volumes rise.read more...
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers
MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.read more...
Benzinga
The Money Machine Is Back, as Biotech, AI, and Tech Names Explode
Today’s stock market coverage illustrates two very different kinds of momentum. NeOnc (NASDAQ:NTHI), MDxHealth (NASDAQ:MDXH), and Capricor Therapeutics (NASDAQ:CAPR) are fundamentally driven healthcare stories, where clinical data, regulatory decisions, diagnostics adoption and cash runway determine whether today's enthusiasm can become a durable rerating, while Wetour Robotics (NASDAQ:WETO), Onfolio Holdings (NASDAQ:ONFO), and Creative Global Technology Holdings (NASDAQ: CGTL) are much more structure-sensitive.
24-7 Market News
Sub-Dollar Cancer Diagnostics Play Erupts on Q2 Revenue
Precision diagnostics is becoming an increasingly important part of modern cancer care as physicians look for better tools to guide treatment decisions and avoid unnecessary procedures. Companies that can translate better testing into measurable revenue growth are beginning to attract serious investor attention.Shares of MDxHealth SA (NASDAQ: MDXH) are surging Friday after the urology focused precision diagnostics company reported second quarter results showing double digit revenue growth and renewed momentum across its core prostate cancer business.Second quarter revenue from continuing ...
AllPennyStocks.com
Sub-Dollar Cancer Diagnostics Play Erupts on Q2 Revenue
Precision diagnostics is becoming an increasingly important part of modern cancer care as physicians look for better tools to guide treatment decisions and avoid unnecessary procedures. Companies that can translate better testing into measurable revenue growth are beginning to attract serious investor attention.Shares of MDxHealth SA (NASDAQ: MDXH) are surging Friday after the urology focused precision diagnostics company reported second quarter results showing double digit revenue growth and renewed momentum across its core prostate cancer business.Second quarter revenue from continuing ...
AllPennyStocks.com
MDxHealth SA (MDXH) Reports Q2 Loss, Beats Revenue Estimates
MDxHealth SA (MDXH) delivered earnings and revenue surprises of -50.00% and +5.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +39.13% and +2.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
TruBridge (TBRG) Surpasses Q1 Earnings Estimates
TruBridge (TBRG) delivered earnings and revenue surprises of +15.69% and -3.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Outset Medical, Inc. (OM) Reports Q1 Loss, Lags Revenue Estimates
Outset Medical (OM) delivered earnings and revenue surprises of -5.06% and -3.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks